Immunogenicity Screening

EpiVax screens for immunogenicity and employs a proprietary scale that compares proteins to antibodies already in clinical use.

Depending on the therapeutic context, biologics have proven to be surprisingly immunogenic. After years of thorough study of the parameters influencing immunogenicity, EpiVax uses proprietary, state-of-the-art immunoinformatics tools and in vitro techniques to predict the potential immunogenicity of proteins. These proteins may be administered for therapeutic purposes (as in enzymes, monoclonals, replacement proteins) or as vaccines.

Immunogenicity screening and placement of drug candidates on an immunogenicity scale is now used to compare one protein therapeutic to another. The immunogenicity scale identifies the best lead candidate to carry forward from preclinical to clinical development, thus reducing the risk of failure due to immunogenicity in the clinical setting.

In silico analysis is at the core of our approach to immunogenicity screening. Using the ISPRI toolkit we can analyze the immunogenic potential of a candidate protein with unprecedented detail. Not only does this approach save time, but it allows researchers to move forward to lab validation or deimmunization in a targeted way. The fastest way to waste money is to go blindly into expensive lab work.

EpiVax screens for Immunogenicity and employs a proprietary scale that compares the protein toantibodies already in clinical use.

The EpiVax Immunogenicity Screening Process. Published in T-cell dependent immunogenicity of protein therapeutics (Jawa, 2013)

Immunogenicity Screening

Depending on the therapeutic context, biologics have proven to be surprisingly immunogenic. After years of thorough study of the parameters influencing immunogenicity, EpiVax uses proprietary, state-of-the-art, immunoinformatics tools and in vitro techniques to predict the potential immunogenicity of proteins, whether these proteins are administered for therapeutic purposes (as in enzymes, monoclonals, replacement proteins) or as vaccines.

Immunogenicity screening and placement of drug candidates on an immunogenicity scale is now used as a means of comparing one protein therapeutic (or mAb) to another, so as to select the best lead to carry forward from preclinical to clinical development, thus reducing the risk of failure due to immunogenicity in the clinical setting.

At the core of our approach to immunogenicity screening is the in silico analysis. Using the ISPRI toolkit we can analyze the immunogenic potential of a candidate protein in depth. Not only does this approach save time, but it allows us to move forward to lab validation or deimmunization in a targeted way. The fastest way to waste money is to go blindly into costly lab work.

EpiVax screens for Immunogenicity and employs a proprietary scale that compares the protein to antibodies already in clinical use.

The EpiVax Immunogenicity Screening Process. Published in T-cell dependent immunogenicity of protein therapeutics (Jawa, 2013)